Thomas Francis DeLaney, MD
Medical Director, Francis H. Burr Proton Therapy Center
Co-Director, Center for Sarcoma and Connective Tissue Oncology
- Department of Radiation Oncology
- Cancer Center
- Radiation Oncology
- Sarcoma and Connective Tissue Oncology
- Osteosarcoma (Bone Cancer)
- Multiple Myeloma
- Clinical Interests
- Brachytherapy (radioactive seeds)
- Proton Radiation Therapy
- Ewing's sarcoma
- Boston: Massachusetts General Hospital
- Medical Education
- MD, Harvard Medical School
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Therapeutic Radiology, American Board of Radiology
- Foreign Languages
- Patient Age Group
- Adult and pediatric
- Accepting New Patients
- Insurances Accepted
- Aetna Health Inc.
Blue Cross Blue Shield - Blue Care 65
Blue Cross Blue Shield - Indemnity
Blue Cross Blue Shield - Managed Care
Blue Cross Blue Shield - Partners Plus
Cigna (PAL #'s)
Fallon Community HealthCare
ForMost Managed Care
Great-West Healthcare (formally One Health Plan)
Harvard Pilgrim Health Plan - ACD
Harvard Pilgrim Health Plan - PBO
Health Care Value Management (HCVM)
Humana/Choice Care PPO
Neighborhood Health Plan - ACD
Neighborhood Health Plan - PBO
OSW - Connecticut
OSW - Maine
OSW - New Hampshire
OSW - New York
OSW - Rhode Island
OSW - Vermont
Private Health Care Systems (PHCS)
Railroad Medicare - ACD
Tufts Health Plan
Tufts Medicare Advantage PPO
United Healthcare (non-HMO) - ACD
United Healthcare (non-HMO) - PBO
Thomas F. DeLaney, M.D. is a graduate of Harvard College and Harvard Medical School. He trained in Radiation Oncology at the Massachusetts General Hospital (MGH) and spent 6 years as Senior Investigator at the National Cancer Institute. Since 1992, he has been on staff at MGH where he is the Medical Director of the Burr Proton Therapy Center and Co-Director of the Center for Sarcoma and Connective Tissue Oncology. He is Associate Professor of Radiation Oncology at Harvard Medical School.
Dr. DeLaney has made important contributions to the treatment of soft tissue and bone sarcomas as well as the use of charged particle (proton) radiation therapy. His bibliography lists 65 original reports as well as 84 reviews and book chapters. He is on the editorial boards of Annals of Surgical Oncology, Journal of Surgical Oncology, Journal of Clinical Oncology.and UpToDate in Oncology.
My major research efforts have been in the development and testing of innovative cancer treatment approaches in clinical trials. Primary areas of interest have been soft tissue and bone sarcomas in adults and adolescents, as well as the application of advanced radiation oncology technologies including charged particle radiation with protons and brachytherapy (i.e. placement of radiation sources in close proximity to the tumor to deliver high doses of radiation to the tumor while sparing nearby normal tissue).
- DeLaney TF et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Rad Oncol Biol Phys. 2003;56:1117-27.
- DeLaney TF et al. Phase II study of high dose photon/proton radiotherapy in the management of spine sarcomas. Int J Rad Oncol Biol Phys 2009; 74: 732-9.
- Kepka L, DeLaney TF, et al. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Rad Oncol Biol Phys 2005; 63:852-9
The MGH Cancer Center has added pencil-beam scanning to the radiation therapy modalities offered at the hospital’s Burr Proton Therapy Center.
Clark Center for Radiation Oncology
100 Blossom Street
Boston, MA 02114-2606
Call the Massachusetts General Hospital physician referral service at 800-711-4644.
Mass General accepts most health insurance plans. Find out what you need to know before coming to Mass General.
Driving to Mass General? Get driving directions or locate a parking lot on the hospital's main campus.